Published in Blood on October 01, 1998
Hereditary thrombophilia. Thromb J (2006) 1.08
A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay. J Mol Diagn (2000) 0.96
Case reports: heritable thrombophilia associated with deep venous thrombosis after shoulder arthroscopy. Clin Orthop Relat Res (2009) 0.96
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92
Anticoagulation management. Semin Intervent Radiol (2010) 0.90
Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag (2007) 0.86
Endothelial Nitric Oxide Synthase T-786C Mutation, Prothrombin Gene Mutation (G-20210-A) and Protein S Deficiency Could Lead to Myocardial Infarction in a Very Young Male Adult. Open Access Maced J Med Sci (2016) 0.82
Protein-C deficiency presenting as pulmonary embolism and myocardial infarction in the same patient. Thromb J (2013) 0.79
Hereditary and acquired thrombophilic disorders complicating vascular access in haemodialysis: O. Sarkar et al. NDT Plus (2010) 0.78
Role of investigating thrombophilic disorders in young stroke. Stroke Res Treat (2011) 0.75
Evaluation of Factor VIII as a Risk Factor in Indian Patients with DVT. Surg Res Pract (2015) 0.75
Assessment of specific risks for the recurrence of deep vein thrombosis: a case report. Cases J (2009) 0.75
Factor V Leiden mutation does not correlate with retinal vascular occlusion in white patients with Behçet's disease. Br J Ophthalmol (2003) 0.75
Inherited trombophilic states and pulmonary embolism. J Res Med Sci (2009) 0.75
Life-threatening aortic thrombosis in a trauma patient homozygous for factor V Leiden mutation: Case report. Thromb J (2011) 0.75
Effects of oral contraceptives on selected parameters of the homeostatic control system in young women having a sudden disorder of the auditory and/or balance system. Eur Arch Otorhinolaryngol (2013) 0.75
A Case of Oral-contraceptive Related Ischemic Colitis in Young Woman. Clin Endosc (2011) 0.75
Paget-Schroetter syndrome in the absence of common predisposing factors: a case report. Thromb J (2017) 0.75
[Retinal vein branch occlusion and palsy of the N. abducens in protein S deficiency]. Ophthalmologe (2005) 0.75
The Successful Prevention of Thromboembolism Using Rivaroxaban in a Patient with Antithrombin Deficiency during the Perioperative Period. Intern Med (2017) 0.75
Internal jugular vein thrombosis associated with venous hypoplasia and protein S deficiency revealed by ultrasonography. J Anesth (2011) 0.75
Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A (1997) 5.83
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol (2001) 5.03
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
The E2F1-3 transcription factors are essential for cellular proliferation. Nature (2001) 4.37
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev (2001) 3.43
Effect of the age at which smoking begins on frequency of smoking in adulthood. N Engl J Med (1991) 2.96
Ras enhances Myc protein stability. Mol Cell (1999) 2.91
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med (1996) 2.51
The accumulation of an E2F-p130 transcriptional repressor distinguishes a G0 cell state from a G1 cell state. Mol Cell Biol (1996) 2.47
Cdc6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl Acad Sci U S A (1998) 2.40
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Ethnic differences in estrogen metabolism in healthy women. J Natl Cancer Inst (1996) 2.29
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study. Neurology (2005) 2.18
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Prostacyclin synthesis induced in vascular cells by interleukin-1. Science (1985) 2.13
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Analysis of the microtopography of the skin by silicone replicas after repeated exposure to actinic radiation at high altitudes. J Eur Acad Dermatol Venereol (2001) 2.04
Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol (2006) 2.02
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Office normotensives with a minimal augmentation of intima-media thickness of common carotid arteries: really normotensives? Eur Rev Med Pharmacol Sci (2013) 1.97
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ (1998) 1.96
E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev (1995) 1.95
Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis (2007) 1.94
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia (2008) 1.92
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia (2006) 1.92
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem (1988) 1.88
Expression of the HsOrc1 gene, a human ORC1 homolog, is regulated by cell proliferation via the E2F transcription factor. Mol Cell Biol (1996) 1.83
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst (1994) 1.74
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Genetic screening for hemophilia A (classic hemophilia) with a polymorphic DNA probe. N Engl J Med (1985) 1.67
Feasibility of a large prospective study in general practice: an Italian experience. Gruppo di Studio sulla Pressione Arteriosa nell'Anziano. Br Med J (Clin Res Ed) (1987) 1.65
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost (2010) 1.62
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Effect on blood coagulation of massive intravascular haemolysis. Blood (1969) 1.61
Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60
Functional analysis of E2F transcription factor. Methods Enzymol (1997) 1.59
Screening of JAK2 V617F mutation in multiple myeloma. Leukemia (2006) 1.59
Monocyte function in intravenous drug abusers with lymphadenopathy syndrome and in patients with acquired immunodeficiency syndrome: selective impairment of chemotaxis. Clin Exp Immunol (1985) 1.57
A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost (2001) 1.57
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost (2012) 1.57
The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol (2001) 1.57
Physical activity is negatively associated with the metabolic syndrome in the elderly. QJM (2008) 1.57
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol (1995) 1.55
A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J Thromb Haemost (2003) 1.53
Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. Proc Natl Acad Sci U S A (1994) 1.51
Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. Blood (1988) 1.50
Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia (2003) 1.49
The role of direct tissue contact in the production of gastrointestinal ulcers by anti-inflammatory drugs in rats. Toxicol Appl Pharmacol (1979) 1.49
Homocysteine, vitamin B12, and serum and erythrocyte folate in peritoneal dialysis and hemodialysis patients. Perit Dial Int (2000) 1.48
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost (2006) 1.48
Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion (1995) 1.48
BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A (2001) 1.48
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med (2010) 1.47
Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol (2001) 1.47
Rare coagulation disorders. Thromb Haemost (1999) 1.46
Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. A report of the Subcommittee for Control of Anticoagulation. Thromb Haemost (1993) 1.45
Risk factors for deep venous thrombosis of the upper extremities. Ann Intern Med (1997) 1.45
Role of the Rb/E2F pathway in cell growth control. J Cell Physiol (1997) 1.44
Alternative approaches to the prognostic stratification of mild to moderate primary vesicoureteral reflux in children. J Urol (1996) 1.44
Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost (1994) 1.43
A simplified procedure for thromboplastin calibration--the usefulness of lyophilized plasmas assessed in a collaborative study. Thromb Haemost (1996) 1.43
Suppression of juvenile chronic myelogenous leukemia colony growth by interleukin-1 receptor antagonist. Blood (1994) 1.43
No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. Hepatology (1996) 1.42
Arg506Gln factor V mutation and cerebral ischemia in the young. Stroke (1996) 1.42
Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. Br J Haematol (1997) 1.42
Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood (1997) 1.41
Longins: a new evolutionary conserved VAMP family sharing a novel SNARE domain. Trends Biochem Sci (2001) 1.41
Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res (2000) 1.41
Factor VII clotting assay: influence of different thromboplastins and factor VII-deficient plasmas. CISMEL Study Group. Thromb Haemost (1991) 1.40
Lipid profile during rhGH therapy in pediatric renal transplant patients. Pediatr Transplant (2002) 1.40
Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol (1993) 1.40
Functional significance of different human CYP1A1 genotypes. Carcinogenesis (1994) 1.40
Frequency of factor V Arg506 Gln in Italians. Thromb Haemost (1996) 1.39